Delisting risk
AIM ImmunoTech
Develops Ampligen as an immunotherapy adjunct for metastatic pancreatic cancer.
$0.2289
Pre-market−0.00 (−0.91%)
At close$0.2310(−10.60%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions18 holders · as of Mar 31, 2026 | 0.58% | 175.8K shares | |
| Otherremainder | 99.42% | 30.27M shares |
30.44M company shares as of Sep 1, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (30.44M in the company's Sep 1, 2026 report, 3.40M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
18 holders · 175.8K shares · 18 new positions · 18 increased · 0 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Virtu Financial LLC | 50.9K | 0.17% | +50.9Knew | May 14, 2026 |
| Geode Capital Management, LLC | 29.9K | 0.10% | +12.5K | May 15, 2026 |
| HRT Financial LP | 26.0K | 0.09% | +26.0Knew | May 14, 2026 |
| XTX Topco Ltd | 20.6K | 0.07% | +20.6Knew | May 15, 2026 |
| Jane Street Group, LLC | 20.0K | 0.07% | +20.0Knew | May 12, 2026 |
| Vanguard Fiduciary Trust Co | 17.5K | 0.06% | +17.5Knew | May 8, 2026 |
| Newedge Advisors, LLC | 5.0K | 0.02% | +5.0Knew | Jun 3, 2026 |
| Tower Research Capital LLC (TRC) | 4.7K | 0.02% | +4.5K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Orca Capital AG | 9.90% | 1.79M | 13G | May 12, 2026 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.